News Image

MERCK & CO. INC. (NYSE:MRK) - A Strong Value Pick in Pharmaceuticals

By Mill Chart

Last update: Jun 10, 2025

MERCK & CO. INC. (NYSE:MRK) stands out as a compelling value stock, selected by our Decent Value screener. The company combines solid profitability, financial health, and reasonable growth prospects—all while trading at an attractive valuation. Below, we break down why MRK may appeal to value-focused investors.

Key Strengths

Valuation (Rating: 9/10)

MRK appears undervalued relative to both its industry and the broader market:

  • P/E Ratio: At 10.18, MRK trades well below the industry average (21.73) and the S&P 500 (26.53).
  • Forward P/E: 8.05 suggests further upside potential.
  • Enterprise Value/EBITDA: Cheaper than 87% of pharmaceutical peers.
  • PEG Ratio: Indicates the stock is reasonably priced relative to expected earnings growth.

Profitability (Rating: 9/10)

The company demonstrates strong earnings power:

  • Return on Equity (ROE): 36.07%, outperforming 97% of industry peers.
  • Operating Margin: 33.84%, ranking in the top 6% of the sector.
  • Profit Margin: 27.27%, well above most competitors.

Financial Health (Rating: 7/10)

MRK maintains a stable balance sheet:

  • Low Debt Risk: Altman-Z score of 3.88 signals financial stability.
  • Debt/FCF Ratio: 2.04 indicates manageable debt levels.
  • Share Buybacks: The company has reduced shares outstanding over the past five years.

Growth (Rating: 5/10)

While growth is moderate, recent performance is encouraging:

  • EPS Growth: Up 259% YoY, with a 5-year average of 8%.
  • Revenue Growth: 10.4% annualized over the past five years.
  • Future Outlook: Analysts expect steady, though slower, earnings growth (~6% annually).

Dividend (Rating: 8/10)

MRK offers an attractive income component:

  • Dividend Yield: 4.17%, above the industry and S&P 500 averages.
  • Dividend Growth: 6.9% annual increase over the past decade.
  • Payout Ratio: 45.5%, suggesting sustainability.

Risks to Consider

  • Slowing Growth: Future revenue and EPS growth projections are modest.
  • Liquidity Metrics: Current and quick ratios are below industry averages, though solvency remains strong.

For a deeper analysis, review the full fundamental report for MRK.

Our Decent Value screener lists more stocks with strong valuations and solid fundamentals.

Disclaimer

This is not investment advice. Always conduct your own research before making investment decisions.

MERCK & CO. INC.

NYSE:MRK (7/1/2025, 8:49:33 PM)

Premarket: 82.19 +0.38 (+0.46%)

81.81

+2.65 (+3.35%)



Find more stocks in the Stock Screener

MRK Latest News and Analysis

ChartMill News Image3 hours ago - ChartmillMERCK & CO. INC. (NYSE:MRK) – A Strong Value Candidate in Healthcare

MERCK & CO. (NYSE:MRK) is an undervalued pharmaceutical stock with strong profitability, a healthy balance sheet, and a reliable dividend, making it a candidate for value investors.

ChartMill News Image14 days ago - ChartmillMERCK & CO. INC. (NYSE:MRK) - A Strong Dividend Stock with Solid Fundamentals

MERCK & CO. (NYSE:MRK) is a top dividend stock with a 3.96% yield, strong profitability, and solid financial health, making it a compelling choice for income investors.

Follow ChartMill for more